The Role of $^{18}$F-FDG PET/CT in the Primary Staging of Gastric Cancer

Mide Kanserinin Primer Evrelesmesinde $^{18}$F-FDG PET/BT’nin Rolü

Mustafa Filik1, Kemal Metin Kir2, Bülent Aksel3, Çiğdem Soydal2, Elgin Özkan2, Özlem Nuriye Küçük2, Erkan İbiş2, Hikmet Akgül3

1Prof. Dr. A. İlhan Özdemir State Hospital, Clinic of Nuclear Medicine, Giresun, Turkey
2Ankara University Faculty of Medicine, Department of Nuclear Medicine, Ankara, Turkey
3Ankara University Faculty of Medicine, Department of Surgical Oncology, Ankara, Turkey

Abstract

Objective: The aim of this study is to explore the role of $^{18}$F-FDG PET/CT in the primary staging of gastric cancer in the comparison of ceCT as routine staging method and evaluate influencing parameters of $^{18}$F-FDG uptake.

Methods: Thirty-one patients (mean age: 58.9±12.6) who underwent $^{18}$F-FDG PET/CT for primary staging of gastric cancer between June 2011 and June 2012 were included to the study. $^{18}$F-FDG PET/CT findings were compared with pathological reports in patients who underwent surgery following PET/CT. $^{18}$F-FDG PET/CT findings of primary lesions, lymph nodes and adjacent organs were compared with ceCT findings and pathological reports. Since 6 patients were accepted as inoperable according to $^{18}$F-FDG PET/CT and/or ceCT and/or laparotomy and/or laparoscopy findings, pathological confirmation could not be possible.

Results: In the postoperative TNM staging of patients, while 1 (4%), 1 (4%), 4 (16%), 2 (8%), 12 (48%) and 5 (20%) patients were staged as T0, Tis, T1, T2, T3 and T4, respectively, 8 (32%), 6 (24%), 6 (24%) and 5 (20%) patients were N0, N1, N2 and N3 respectively. $^{18}$F-FDG PET/CT was totally normal in 2 patients. While primary tumors were FDG avid in 27 patients, in 17 and 6 patients FDG uptake was observed in perigastric lymph nodes and distant organs, respectively. Mean SUVmax of FDG avid tumors was calculated as 13.49±9.29 (3.00-44.60). However, SUVmax of lymph nodes was computed as 9.28±6.92 (2.80-29.10). According to sub-analysis of histopathological subtypes of primary tumors, SUVmax of adenocarcinomas was calculated as 15.16 (3.00-44.60), of signet ring cells as 9.90 (5.50-17.70), of adenocarcinomas with signet ring cell component as 11.27 (6.20-13.90) (p=0.721). In the comparison with histopathological examination while ceCT was TP, TN, FN in 23, 1 and 1 patients, $^{18}$F-FDG PET/CT was TP, FP, FN in 20, 1 and 4 patients, respectively. Sensitivity, specificity, accuracy, PPD and NPV of ceCT in the detection of lymph node metastasis was calculated as 83.3%, 75%, 80%, 87.5% and 66.6%, respectively. These parameters for $^{18}$F-FDG PET/CT were 64.7%, 100%, 76%, 100% and 57.1%.

Conclusion: Despite lower sensitivity than ceCT, diagnostic power of $^{18}$F-FDG PET/CT in the preoperative staging of gastric cancer is acceptable. Because of its high PPV, it might be beneficial in the evaluation of patients with suspected lymph nodes. The role of $^{18}$F-FDG PET/CT seems to be limited in the early stage and signet ring cell carcinomas due to lower $^{18}$F-FDG uptake.

Key words: Gastric cancer, cancer staging, positron emission tomography/computed tomography, lymphatic metastasis

Conflicts of Interest: The authors reported no conflict of interest related to this article.

Adresse for Correspondence: Mustafa Filik MD, Prof. Dr. A. İlhan Özdemir State Hospital, Clinic of Nuclear Medicine, Giresun, Turkey
Phone: +90 454 310 20 00 E-mail: mfilik77@gmail.com Received: 08.10.2014 Accepted: 25.12.2014

Molecular Imaging and Radionuclide Therapy, published by Galenos Publishing.
Introduction

Gastric cancer is the one of the commonest cancers worldwide. Moreover, it is the most common and fatal cancer in most Eastern Countries. While incidence of gastric cancer has a decreasing trend, esophageal and gastro-esophageal junction cancers have been increasing (1,2). About 80% of gastric cancer patients have been diagnosed in the advanced stage of the disease (3).

Curative surgical resection is the only method for taking disease under control. The primary aim of curative surgery is not letting to leave any microscopic or macroscopic tumor left with appropriate lymphadenectomy and gastric resection. Mortality rate due to surgical procedures is about 1%. To decrease mortality and morbidity rates, inclusion of only appropriate candidates for surgical procedure and selection of appropriate lymph node dissection (D1, D2 or D3) accompanying gastric resection are mandatory. For these reasons, characterization of disease and correct preoperative staging of patients are very important. Contrast enhanced computed tomography (ceCT), magnetic resonance imaging (MRI), endoscopic ultrasound (EUS), laparoscopy and peritoneal fluid cytology are the choice of the techniques for the staging of gastric cancer (4,5,6). Although it is the standard method for preoperative staging of gastric cancer, ceCT has limitations in the detection of peritoneal implants and regional lymph node metastases (7,8).

The routine use of 18-Flouro-Deoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) in the imaging of upper gastrointestinal system malignancies has been increased in the last decade. In esophageal cancer patients, 18F-FDG PET/CT could help to discriminate resectable and unresectable disease and prevent unnecessary surgical procedures (9). Prognostic value of 18F-FDG PET/CT and its role in the chemotherapy response evaluation have been demonstrated (10,11,12,13). Contrarily, its role in the gastric cancer is controversial. First limitation of 18F-FDG PET/CT arises from variable and sometimes intense physiological uptake in the gastric mucosa. Moreover acute inflammatory causes such as gastritis can be reasons for false positive FDG uptake (14,15,16). Additionally, in the different subtypes of gastric cancer, 18F-FDG uptake can be altered due to different expressions of glucose transport proteins (17).

Several studies have been designed to investigate the role of 18F-FDG PET or 18F-FDG PET/CT in comparison with ceCT in the preoperative staging of gastric cancer. In the first studies, it has been showed that sensitivity of 18F-FDG PET/CT is lower and specificity is higher than CT in the detection of regional and distant lymph node metastases (18,19,20). Although National Comprehensive Cancer Network (NCCN) recommends the use of 18F-FDG PET/CT in the preoperative staging of gastric cancer, there is no consensus on its benefit (21).

The aim of this study is explore the role of 18F-FDG PET/CT in the primary staging of gastric cancer in comparison with ceCT as routine staging method and evaluate influencing parameters of 18F-FDG uptake.

Bulgular: Hastalar postoperatif histopatoloji sonuçları ile TNM evrelemesine göre değerlendirildiğinde, 1 hasta T0 (%4), 4 hasta Tis (%4), 4 hasta T2 (%8), 2 hasta T3 (%8), 12 hasta T4 (%48), 5 hasta T4 (%20) olarak saptandı. Cerrahi sonrası N evresine göre ise 8 hasta N0 (%32), 6 hasta N1 (%24), 6 hasta N2 (%24), 5 hasta N3 (%20) olarak kabul edildi. 18F-FDG PET/CT, 2/31 hasta normal, 27/31 hasta midede primer tümörde, 17/31 hasta perigastrik lenf nodlarından, 6/31 hasta uzak organda patolojik 18F-FDG tutulumu olarak raporlandı. Midede primer lezyonda 18F-FDG tutulumu izlenen hastaların oratalama SUVmax değeri 13,49±9,29 (3,00-44,40) olarak hesaplanırken, lenf nodunda aktivite tutulumu izlenen hastaların oratalama SUVmax değeri 9,28±6,92 (2,50-29,10) olarak hesaplandı. Hastaların histopatolojik tanılarına göre primer tümörde 18F-FDG tutulumunu incelendiğinde, oratalama SUVmax, adenokarsinomda 15,16 (3,00-6,40) taşlı yüzük hücreli karsinomda 9,90 (5,50-17,70), taşlı yüzük hücre komponenti bulunduran adenokarsinomda 11,27 (6,20-13,90) olarak hesaplandı (p=0,721). BT sonu operatif histopatoloji sonuçları ile değerlendirildiğinde, primer lenfonun saptanmasıyla BT 23/25 hasta GP, 1/25 hasta GN, 1/25 hasta ise YN olarak değerlendirildi. 18F-FDG PET/CT ise, 20/25 hasta GP, 1/25 hasta GP, 4/25 hasta GN, 1/25 hasta YN olarak değerlendirildi. BT'nin lenf nodu metastazını saptamada duyarlılık, özgülük, doğruluğu, PPV ve NPD'si sırasıyla, %83,3, %67,5, %66,6, %66 olarak hesaplandı. 18F-FDG PET/CT'nin lenf nodu metastazını saptamada duyarlılık, özgülük, doğruluğu, PPV ve NPD'si sırasıyla %64,7, %100, %76, %100, %57,1 olarak hesaplandı. NPV, 4/25 hasta Tis (%4), 4/25 hasta T1 (%16), 2/25 hasta T2 (%8), 12/25 hasta T3 (%48), 5/25 hasta T4 (%20) olarak saptandı. Cerrahi sonrası N evrelerine göre ise 8 hasta N0 (%32), 6 hasta N1 (%24), 6 hasta N2 (%24), 5 hasta N3 (%20) olarak kabul edildi. 18F-FDG PET/CT'nin N evresini saptamada duyarlılık, özgülük, doğruluğu, PPV ve NPD'si sırasıyla %83,3, %100, %76, %100, %57,1 olarak hesaplandı.

Sonuç: Mide kanserinin cerrahi ön öncesi evrelemesinde 18F-FDG PET/BT'nin tansal güçü BT'ye göre düşük olamakla birlikte kışlayabilir bir düzeydedir. Bölgesel lenfonunun saptanmasıyla, BT'nin saptanması ile belirtilen lenf nodu saptanan hastaların değerlendirilmesinde yararlı olabilir. Diğer histolojik alt tiplerde daha yüksek düzeyde 18F-FDG tutulumu izlenen taşlı yüzük hücreli karsinom veya erken evre mide kanseri oğulları cerrahi öncesi evrelemesinde 18F-FDG PET/BT'nin rolü sınırlı görülmektedir.

Anahtar Kelimeler: Mide kanseri, kanser evrelemesi, pozitron emisyon tomografi/bilgisayarlı tomografi, lenfatik metastaz

Çıkar Çatışması: Yazarlar bu makale ile ilgili herhangi bir çıkar çatışması bildirmemiştir.

Filik et al. 18F-FDG PET/CT in Gastric Cancer
Material and Methods

Patients
Thirty-one patients (mean age: 58.9±12.6 years) who underwent 18F-FDG PET/CT for primary staging of gastric cancer between June 2011 and June 2012 were included in the study. Diagnosis of all patients had been proved by endoscopic and histopathological examination of upper gastrointestinal system.

18F-FDG PET/CT Imaging
PET/CT images were acquired with GE Discovery ST PET/CT scanner. Patients fasted at least 6 hours before imaging and blood glucose levels were checked. Those with a blood glucose level above 150 mg/dL did not undergo scanning. Oral contrast was given to all patients. Images from the vertex to the proximal femur were obtained while the patients were in the supine position. Whole body 18F-FDG PET/CT imaging was performed approximately 1 hour after an intravenous injection of 8-10 mCi 18F-FDG. During the waiting period, patients rested in a quiet room without taking any muscle relaxants. PET images were acquired for 4 minutes per bed position. Emission PET images were reconstructed with non-contrast CT images. CT images were also obtained from the patient’s integrated 18F-FDG PET/CT with the use of a standardized protocol of 140 kV, 70 mA, tube rotation time of 0.5 s per rotation, a pitch of 6 and a slice thickness of 5 mm. Patients were allowed to breathe normally during the procedure. Attenuation-corrected PET/CT fusion images were reviewed in three planes (transaxial, coronal and sagittal) on a Xeleris Workstation 4.2 (GE Medical Systems).

Image Analysis
18F-FDG PET/CT images were evaluated visually and semi-quantitatively in three planes (trans-axial, coronal and sagittal). Anatomical confirmation of lesions with higher uptake than adjacent tissues and blood pool activity has been performed by low dose CT images.

Data Analysis
18F-FDG PET/CT findings were compared with pathological reports in patients who underwent surgery following PET/CT. 18F-FDG PET/CT findings of primary lesions, lymph nodes and adjacent organs were compared with ceCT findings and pathological reports. In 6 patients who were accepted as inoperable according to 18F-FDG PET/CT and/or ceCT and/or laparotomy and/or laparoscopy findings, pathological confirmation could not be possible.

Statistical Analysis
18F-FDG uptake of primary tumors and abdominal lymph nodes were analyzed. Because gastric cancer diagnoses had been proved before PET/CT imaging, sensitivity and specificity of 18F-FDG PET/CT in distinguishing benign and malign lesions could not be evaluated. However SUVmax of primary lesions according to histopathological subtype have been compared. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of 18F-FDG PET/CT in the detection of lymph node metastasis have been calculated. Fisher Exact test was used in the comparison of CT and 18F-FDG PET/CT findings. Kruskal-Wallis Test was performed in the comparison of relationship between SUVmax of primary lesions and lymph nodes based on histopathological subtypes.

Results
During the study period, 31 patients (24 M; 7 F, mean age: 58.9±12.6 years) underwent 18F-FDG PET/CT for staging of gastric cancer. Twenty-five patients underwent curative surgery including gastrectomy and lymph node dissection following PET/CT. Six patients have been accepted inoperable. Postoperative histopathological examination results of 14, 4, 4, 1, 1 and 1 patients were adenocarcinoma, signet ring cell carcinoma, adenoacarcinoma with signet ring cell component, papillary adenoacarcinoma, adenosquamous carcinoma and intestinal metaplasia without residual tumor, respectively.

In the postoperative TNM staging of patients, while 1 (4%), 1 (4%), 4 (16%), 2 (8%), 12 (48%) and 5 (20%) patients were staged as T0, Tis, T1, T2, T3 and T4, respectively, 8 (32%), 6 (24%), 6 (24%) and 5 (20%) patients were N0, N1, N2 and N3 respectively. Twenty percent (n=5) of the patients was early stage gastric cancer (T1, N any). Inoperability decision was taken by peritoneal fluid cytology in 2, by ceCT and PET/CT findings in 2, by liver wedge resection in 1 and detection of adjacent organ involvement during laparotomy in 1 patient.

All the patients underwent abdominal ceCT before PET/CT. While ceCT was normal in 2 patients, increase in wall thickness or gastric mass was detected in 29, perigastric/abdominal lymph nodes in 21, distant organ metastases in 8 and peritonitis carcinoma in 1 patient.

18F-FDG PET/CT was normal in 2 patients. Postoperative histopathological reports of these patients were multifocal intramucosal adenocarcinoma (Tis) and signet ring cell carcinoma. Pathological 18F-FDG uptake was detected in primary tumor in 27, perigastric lymph nodes in 17 and distant organs in 6 patients. In two patients with non-FDG avid primary tumor, lymph node or distant organ metastases were FDG avid. Mean SUVmax of FDG avid primary tumors and lymph nodes were calculated as 13.49±9.29 (3.00-44.60) and 9.28±6.92 (2.80-29.10), respectively. Mean SUVmax of T1, T3 and T4 patients were 11.66 (3.00-25.30), 16.31 (4.60-44.60) and 10.32 (5.5-18.70), respectively (p=0.824). According to comparison of histopathological subtypes, mean SUVmax of adenocarcinomas, signet ring cell carcinomas and adenoacarcinomas with signet ring cell component were 15.16 (3.00-44.60), 9.90 (5.50-17.70) and 11.27 (6.20-13.90), respectively (p=0.721) (Figure 1).
In the detection of primary lesion, while ceCT was TP, TN and FN in 23, 1 and 1 patients, PET/CT was TP, FP and FN in 20, 1 and 4 patients, respectively. Postoperative histopathological examination of 1 FP patient was chronic atrophic gastritis with intestinal metaplasia. In the histopathological examination, signet ring cell carcinoma, early stage adenocarcinoma (T1N1), advanced stage adenocarcinoma (T3N1) and multifocal intramucosal adenocarcinoma (Tis) were detected in FN patients.

In the evaluation of the detection of lymph node metastasis, ceCT was TP, FP, TN and FN in 14, 2, 6 and 3 patients and 18F-FDG PET/CT was TP, TN and FN in 11, 8 and 6 patients, respectively (Table 1). Sensitivity, specificity, accuracy, PPV and NPV of ceCT in the detection of lymph node metastasis was calculated as 83.3%, 75%, 80%, 87.5% and 66.6%, respectively. These parameters were 64.7%, 100%, 76%, 100% and 57.1%, for PET/CT respectively.

In the postoperative histopathological examinations, peritoneal metastases were detected in 5 patients. ceCT and 18F-FDG PET/CT could not detect peritoneal metastases of these patients.

18F-FDG uptake was seen in distant organs in 6 patients (liver: 2, lung: 2, adrenal gland: 1, bone: 2 and distant lymph nodes: 2 patients). Four out of 6 patients have been accepted as inoperable. 18F-FDG PET/CT was FP in one patient with uptake in adrenal gland. Additionally 18F-FDG PET/CT could not detect liver metastasis and peritoneal metastasis in 2 patients.

**Discussion**

Successful preoperative staging of gastric cancer is crucial for evaluation of curability of disease and selection of reasonable treatment options. ceCT still has an important role in this purpose. However ceCT has some limitations in the evaluation of lymph node metastasis, peritoneal involvement and hematological dissemination. 18F-FDG PET/CT has been performed in the preoperative staging of several cancers as well as detection of recurrent disease. Recently, 18F-FDG PET/CT has been used for detection of recurrent gastric cancer with its comparable accuracy with ceCT (22).

Routine use of 18F-FDG PET/CT in the preoperative staging of several cancers has been increasing. However its benefit in the staging of gastric cancer is still controversial. In the first clinical studies, sensitivity, specificity and accuracy of 18F-FDG PET/CT in the detection of primary tumor has been reported as 93%, 100% and 95%, respectively (23). In the following studies, its sensitivity in the detection of primary tumor and recurrence has been found as low as 60% (24, 25, 26). Young KE et al. reported sensitivity of PET/CT and ceCT as 93% and 90% in the detection of primary tumor in advanced stage gastric cancer (18). In our study primary tumor was detected with ceCT in 23 and by 18F-FDG PET/CT in 20 patients. In previous studies detection rate of ceCT for primary tumor in early stage patients have been reported low (26-53%) (27, 28). Shimizu K et al. have found that detection rate of mucosal cancers is lower than those are submucosal (16.6 vs 68.8%) (29). Similarly, Tae et al. have reported that detection rate of mucosal cancers is 35% while it is 58.8% in submucosal ones (30). In our study postoperative histopathological reports of 2 out of 4 patients with FN result revealed early stage gastric cancer. Early stage gastric cancer (ESGC) is described as adenocarcinoma limited in mucosa or submucosa without regarding lymph node metastasis. In the studies that are designed to evaluate lymph node metastasis rates in ESGC, mean lymph node metastasis rates have been reported between 10% and 20% (31, 32). We found higher lymph node metastasis rate in our study (20%).

**Table 1. Comparison of 18F-FDG PET/CT findings and histopathology in the evaluation of lymph node metastasis**

| Histopathology | 18F-FDG PET-CT |
|----------------|----------------|
|                | Positive (n)   | Negative (n) |
| Metastatic     | 11             | 6             |
| Nonmetastatic  | 0              | 8             |

**Table 2. Sensitivity, specificity, accuracy, positive predictive value and negative predictive value of computerized tomography and 18F-FDG PET/CT in the detection of lymph nodes metastasis**

|                  | Sensitivity (%) | Specificity (%) | Accuracy (%) | PPV (%) | NPV (%) |
|------------------|-----------------|-----------------|--------------|---------|---------|
| ceCT             | 83.3            | 75              | 80           | 87.5    | 66.6    |
| 18F-FDG PET/CT   | 64.7            | 100             | 76           | 100     | 57.1    |

PPV: Positive predictive value, NPV: Negative predictive value CT: Computerized tomography
Cellular $^{18}$F-FDG uptake is mostly related to glucose transporter I (GLUT-1) expression level. Although almost every type of cells expresses GLUT-1, malignant cells express higher levels. Exceptionally, GLUT-1 expression is very low in signet ring cell and mucinous carcinomas (33). For this reason, histological subtype of gastric cancer highly affects the detection rates of primary tumor and its metastases by $^{18}$F-FDG PET/CT. In a few studies lower detection rate of signet ring cell carcinoma has been reported (35.3%) (30,34,35). Similarly, in our study, 25% of patients without FDG uptake had signet ring cell carcinoma. In accordance with the literature, we found higher mean SUVmax in adenocarcinomas than signet ring cell carcinoma. However difference between subgroups has not reached to significant level.

Sensitivity of $^{18}$F-FDG PET in the detection of lymph node metastasis is low due to limited spatial resolution of PET. Moreover, evaluation of perigastric lymph nodes could be difficult related to high uptake of primary tumor or normal stomach wall (36). Specificity and sensitivity of $^{18}$F-FDG PET in the detection of lymph node metastasis have been reported as 21-40% and 89-100% (37,38). Combined $^{18}$F-FDG PET/CT systems can localize primary tumor and lymph nodes more precisely and give anatomical and functional information together. In the literature, sensitivity and specificity of $^{18}$F-FDG PET/CT in the detection of lymph node metastasis have been reported as 41-51% and 86-100% (18,30). Similarly to the literature we found sensitivity and specificity of $^{18}$F-FDG PET/CT in the detection of lymph node metastasis as 64.7% and 100%. FDG-PET has a better positive predictive value for lymph node metastasis in comparison with CT, which may alter planning of therapy, as treatment strategy changes due to especially N3 lymph node metastasis from curative surgery to a palliative strategy (36). Inclusion of intravenous contrast agent enhanced CT protocols during PET/CT procedures could increase sensitivity of $^{18}$F-FDG PET/CT especially in the distinguishing perigastric lymph nodes (18). Presence of peritoneal metastasis has been accepted as distant organ metastasis according to recent TNM staging system. Sensitivity of PET and ceCT in the detection of peritoneal metastasis has been reported as 20-35% and 50-77%, respectively (18,19,20). Despite of its low sensitivity, specificity of $^{18}$F-FDG PET/CT in the detection of peritoneal metastases is relatively higher than ceCT (between 63-99%, median 88.5%). Combined usage of high sensitivity ceCT and high specificity PET might be more appropriate than to use them alone. Unnecessary surgical procedures might be avoided by addition of diagnostic laparoscopy in patients with suspected findings (36). Surprisingly, in our study none of patients with peritoneal metastasis could be revealed with ceCT or $^{18}$F-FDG PET/CT.

There are some limitations of this study. Firstly patient number is limited to perform more detailed statistical analysis. Secondly, because $^{18}$F-FDG PET/CT was performed in patients with endoscopically proven gastric cancer, we could not analyze its role in the detection of primary tumor.

Conclusion

Despite its lower sensitivity than ceCT, diagnostic power of $^{18}$F-FDG PET/CT in the preoperative staging of gastric cancer is acceptable. Because of its high PPV, it might be beneficial in the evaluation of patients with suspected lymph nodes. The role of $^{18}$F-FDG PET/CT seems to be limited in the early stage and signet ring cell carcinomas due to lower $^{18}$F-FDG uptake.

References

1. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991;265:1287-1289.
2. Yang GY, Ott K. Accomplishments in 2008 in the management of esophageal cancer. Gastrointest Cancer Res 2009;3:53-57.
3. Roukos DH. Current status and future perspectives in gastric cancer management. Cancer Treat Rev 2000;26:243-255.
4. Abdalla EK, Pisters PW. Staging and preoperative evaluation of upper gastrointestinal malignancies. Semin Oncol 2004;31:513-529.
5. Kwee RM, Kwee TC. Imaging in local staging of gastric cancer: A systematic review. J Clin Oncol 2007;25:2107-2116.
6. Webster WA, Ott K. Imaging of esophageal and gastric cancer. Semin Oncol 2004;31:530-541.
7. Miller FH, Kochman ML, Talamonti MS, Ghahremani GG, Gore RM. Gastric cancer. Radiologic staging. Radiol Clin North Am 1997;35:331-349.
8. Fukuya T, Honda H, Hayashi T, Kaneko K, Tateshi Y, Tetsu Y, Maehara Y, Tanaka M, Tsuneyoshi M, Masuda K. Lymph-node metastases: efficacy for detection with helical CT in patients with gastric cancer. Radiology 1995;197:705-711.
9. Kostakoglu L, Agress H Jr, Goldsmith SJ. Clinical role of FDG PET in evaluation of cancer patients. Radio Graphics 2003;23:315-340.
10. Pan L, Gu P, Huang G, Xue H, Wu S. Prognostic significance of SUV on PET/CT in patients with esophageal cancer: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2009;21:1008-1015.
11. Weber WA, Ott K, Becker F, Dittler HJ, Helmberger H, Avril NE, Mesetschlager G, Busch R, Sievert JR, Schwaiger M, Fink U. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastrojunction by metabolic imaging. J Clin Oncol 2001;19:3058-3065.
12. Ott K, Weber WA, Lordick F, Becker K, Busch R, Herrmann K, Wieder H, Fink U, Schweiger M, Sievert JR. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastrointestinal junction. J Clin Oncol 2006;24:4692-4698.
13. Lordick F, Ott K, Krause BJ, Weber WA, Becker K, Stein HJ, Lorenzen S, Schuster T, Wieder H, Herrmann K, Bredenkamp R, Höfler H, Fink U, Peschel C, Schweiger M, Sievert JR. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 2007;8:797-805.
14. Mochiki E, Kuwano H, Kanoh H, Asao T, Oriuchi N, Endo K. Evaluation of $^{18}$F-2-deoxy-2-fluoro-D-glucose positron emission tomography for gastric cancer. World J Surg 2004;28:247-253.
15. Koga H, Sasaki M, Kawai T, Hiraoka Y, Hiraka K, Nakagawa M, Abe K, Kaneko K, Hayashi K, Honda H. An analysis of the physiological FDG uptake pattern in the stomach. Ann Nucl Med 2003;17:733-738.
16. Takahashi H, Ukawa K, Okawa N, Kato K, Hayashi Y, Yoshimoto K, Ishiyama A, Ueki N, Kuraoka K, Tsuchida T, Yamamoto Y, Chino A, Uragami N, Fujisaki J, Igarashi M, Fujita R, Koyama M, Yamashita T. Significance of $^{18}$F-2-deoxy-2-fluoro-D-glucose accumulation in the stomach on positron emission tomography. Ann Nucl Med 2009;23:391-397.
17. Mukai K, Ishida Y, Okajima K, Itozaki H, Morimoto T, Nishiyama S. Usefulness of preoperative FDG-PET for detection of gastric cancer. Gastric Cancer 2006;9:192-196.
18. Kim EY, Lee WJ, Choi D, Lee SJ, Choi JY, Kim BT, Kim HS. The value of PET/CT for preoperative staging of advanced gastric cancer: comparison with contrast-enhanced CT. Eur J Radiol 2011;79:183-188.

19. Yang OM, Kawamura T, Itoh H, Bando E, Nemoto M, Akamoto S, Furukawa H, Yonemura Y. Is PET-CT suitable for predicting lymph node status for gastric cancer? Hepatogastroenterology 2008;55:782-785.

20. Lim JS, Kim MJ, Yun MJ, Oh YT, Kim JH, Hwang HS, Park MS, Cha SW, Lee JD, Noh SH, Yoo HS, Kim KW. Comparison of CT and 18F-FDG PET for detecting peritoneal metastasis on the preoperative evaluation for gastric carcinoma. Korean J Radiol 2006;7:249-256.

21. National Comprehensive Cancer Network (NCCN) guidelines. Version 2.2012

22. Sim SH, Kim YJ, Oh DY, Lee SH, Kim DW, Kang WJ, Im SA, Kim TY, Kim WH, Heo DS, Bang YJ. The role of PET/CT in detection of gastric cancer recurrence. BioMedCentral Cancer 2009;9:73.

23. Yeung HW, Macapinlac H, Karpeh M, Finn RD, Larson SM. Accuracy of FDG-PET in gastric cancer. Preliminary experience. Clinical Positron Imaging 1998;1:213-221.

24. Stahl A, Ott K, Weber WA, Becker K, Link T, Siewert JR, Schwaiger M, Fink U. FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging 2003;30:288-295.

25. Yun M, Lim JS, Noh SH, Hyung WJ, Cheong JH, Bong JK, Cho A, Lee JD. Lymph node staging of gastric cancer using (18)F-FDG PET: a comparison study with CT. J Nucl Med 2005;46:1582-1588.

26. Park MJ, Lee WJ, Lim HK, Park KW, Choi JY, Kim BT. Detecting recurrence of gastric cancer: the value of FDG PET/CT. Abdom Imaging 2009;34:441-447.

27. Minami M, Kawauchi N, Itai Y, Niki T, Sasaki Y. Gastric tumors: radiologic-pathologic correlation and accuracy of T staging with dynamic CT. Radiology 1992;185:173-178.

28. Fukuya T, Honda H, Hayashi T, Kaneko K, Tateshi Y, Ro T, Maehara Y, Tanaka M, Tsuneyoshi M, Masuda K. Lymph-node metastases: efficacy for detection with helical CT in patients with gastric cancer. Radiology 1995;197:705-711.

29. Shimizu K, Ito K, Matsunaga N, Shimizu A, Kawakami Y. Diagnosis of gastric cancer with MDCT using the water-filling method and multiphase reconstruction: CT-histologic correlation. AJR Am J Roentgenol 2005;185:1152-1158.

30. Ha TK, Choi YY, Song SY, Kwon SJ. F18-fluorodeoxyglucose-positron emission tomography and computed tomography is not accurate in preoperative staging of gastric cancer. Korean Surg Soc 2011;81:104-110.

31. Roviello F, Rossi S, Marrelli D, Pedrazzani C, Corso G, Vindigni C, Morgagni P, Saragoni L, de Mansoni G, Tomezzoli A. Number of LN metastases and its prognostic significance in early gastric cancer: A multicenter Italian study. J Surg Oncol 2006;94:275-280.

32. Gotoda T, Yanagisawa A, Sasako M, Ono H, Nakanishi Y, Shimoda T, Kato Y. Incidence of LN metastasis from early gastric cancer: Estimation with a large number of cases at two large centers. Gastric Cancer 2000;3:219-225.

33. Kawamura T, Kusakabe T, Sugino T, Watanabe K, Fukuda T, Nashimoto A, Honma K, Suzuki T. Expression of glucose transporter-1 in human gastric carcinoma: association with tumor aggressiveness, metastasis, and patient survival. Cancer 2001;92:634-641.

34. Kim SK, Kang KW, Lee JS, Kim HK, Chang HJ, Choi JY, Lee JH, Ryu KW, Kim YW, Bae JM. Assessment of lymph node metastases using 18F-FDG PET in patients with advanced gastric cancer. Eur J Nucl Med Mol Imaging 2006;33:148-155.

35. Chen J, Cheong JH, Yun MJ, Kim J, Lim JS, Hyung WJ, Noh SH. Improvement in preoperative staging of gastric adenocarcinoma with positron emission tomography. Cancer 2005;103:2383-2390.

36. Dassen A.E, Lips DJ, Hoekstra CJ, Pruijt JF, Bosscha K. FDG-PET has no definite role in preoperative imaging in gastric cancer. EJSO 2009;35:449-455.

37. Tsujimoto H, Sugasawa H, Ono S, Ichiura T, Yamamoto T, Kameyama J, Hase K. Has the accuracy of preoperative diagnosis improved in cases of early-stage gastric cancer? World J Surg 2010;34:1840-1846.

38. Mochiki E, Kuwano H, Katoh H, Asao T, Onouchi N, Endo K. Evaluation of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography for gastric cancer. World J Surg 2004;28:247-253.